Date of prep: December 2020
Prescribing information and
adverse events reporting
For healthcare professionals only
The UK Government has come out and made a statement about the recent controversy that ACE-I or ARBs may worsen COVID-19.
The Government has stated that there is no evidence from clinical or epidemiological studies that treatment with ACE-I or ARBs might worsen COVID-19 infection.
They have stated that if people are taking angiotensin-converting enzyme inhibitors (ACE inhibitors or ACE-i) or angiotensin receptor blockers (ARBs) to treat high blood pressure, it is vitally important that they continue their usual treatment.
Whilst some media reports and publications have suggested that treatment with ACE-I or ARBs might worsen COVID-19 infection, there is no evidence from clinical or epidemiological studies to support this.
The Government has said that they recognise the concern that the COVID-19 outbreak is causing, and have assured the public that they are working closely with the Commission on Human Medicines and other regulatory bodies to ensure we can respond with further advice on this issue, should any new data emerge.
Pharmacy in Practice is a UK pharmacy publication with its roots in Scotland.